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Introduction
Lung cancer has long been the most common cause of cancer 
death worldwide, claiming 1.7 million lives annually (1). 
Non-small cell is the most common type of lung cancer 
diagnosed, and approximately 25% of patients will present 
with locally advanced disease (2). Locally advanced disease 
is typically defined as American Joint Committee on 
Cancer stage III, with unresectable primary tumors (T4) 
or involvement of lymph nodes in the mediastinum (N2) 
or supraclavicular fossa (N3) (3). While locally advanced 
disease is curable, patient outcomes unfortunately remain 
poor despite both radiation therapy, chemotherapy, and 
now immunotherapy having improved over time.
The foundation of treatment for locally advanced disease 
is radiation therapy. Radiation is usually combined with 
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concurrent platinum-based chemotherapy, as several trials 
and a meta-analysis have shown improved overall survival 
and local control with concurrent rather than sequential 
treatment (4). Control of disease with concurrent therapy 
remains challenging, however, with 2-year progression 
free survival at just 20–30%. Though the development of 
distant metastases is most common with approximately 
50% of patients experiencing this at 2 years, 30–40% of 
patients also develop local failure in 2 years (5). Resection 
after concurrent chemoradiation therapy show that this 
combination of radiation and chemotherapy only leads to 
complete response in 35–45% of patients (6,7). This review 
will focus on escalation of the total radiation dose used for 
treatment, as well as changes to dose and fractionation that 
are being explored in attempts to improve local control and 
outcomes in locally advanced disease.
Conventional fractionation
Radiation therapy for locally advanced non-small cell lung 
cancer (NSCLC) is most commonly given in fractions of 
1.8 to 2.0 Gy once a day for five days a week with external 
beams. Radiation Therapy Oncology Group (RTOG) 
7301 established a dose of 60 Gy as the standard, after 
escalating the total dose from 40 Gy in a split course, then 
to continuous delivery from 40, to 50, and finally to 60 Gy, 
with the higher doses having higher intrathoracic tumor 
control rates (8). It should be noted that this dose escalation 
was done in the two dimensional era when plans were 
made on based upon X-rays. This was before computed 
tomography (CT) scanners were used in the clinic. Since 
then, advances in radiation treatment have included three 
dimensional CT-based conformal treatment planning, 
the use of positron emission tomography (PET) for more 
accurate staging and targeting, and accounting for tumor 
motion during treatment.
Traditionally, external beam radiation therapy for locally 
advanced NSCLC targeted the primary tumor as well as 
the ipsilateral hilar and mediastinal nodal stations, and 
sometimes even the supraclavicular fossa. This was done 
even without evidence of involvement in these regions and 
is known as elective nodal irradiation. This was done to 
control any microscopic disease in areas felt to be high risk 
for regional metastases. The concern with elective nodal 
irradiation, however, is that it will limit dose escalation as 
the larger volume irradiated will lead to otherwise avoidable 
pulmonary, cardiovascular, and esophageal toxicity. Three 
randomized trials on its use and several cohorts have been 
reported. A meta-analysis of these studies shows the overall 
incidence of elective nodal failure was 5.5% without elective 
nodal irradiation and 3.4% with it (P=0.64 assuming a fixed-
effects mode) (9). Given this lack of a significant difference, 
radiation is now most often prescribed only to gross disease 
that is enlarged on CT or hypermetabolic on PET.
Conventional dose escalation
In attempts to improve local control, radiation dose 
escalation with conventional fractionation and concurrent 
chemotherapy was performed by several groups in phase I 
and II trials. RTOG 0117 escalated to 75.25 Gy in 2.15 Gy 
daily fractions prescribed to the isocenter. Three of the eight 
patients who received 75.25 Gy developed dose-limiting 
pulmonary toxicity, one of which was fatal. The maximum 
tolerated radiation dose was therefore determined to be 
74 Gy in 2 Gy fractions (10). North Central Cancer 
Treatment Group (NCCTG) 0028 escalated from 
70 Gy up in 4 Gy increments. Similar to RTOG 0117, the 
maximum tolerated dose was also determined to be 74 Gy. 
Two of four patients experienced dose limiting pneumonitis 
at 78 Gy (11). The University of North Carolina first 
escalated from 60 to 74 Gy both with limited elective nodal 
radiation and with induction and concurrent chemotherapy, 
then later from 74 to 90 Gy showing grade 3 or greater 
late complications in 22% of patients (12). Cancer and 
Leukemia Group B (CALGB) 30105 was a phase II trial 
treating at 74 Gy and randomizing between gemcitabine 
and paclitaxel used in both induction and concurrent 
treatment (13). Aside from the gemcitabine arm of this trial 
which closed early due to high toxicity, most of these trials 
showed a median survival of around 2 years. 
These trials then led to the multi-institutional 
randomized controlled phase III trial RTOG 0617. In this 
2×2 factorial design trial, patients with stage III NSCLC all 
received weekly carboplatin and paclitaxel chemotherapy 
with concurrent radiation in 2 Gy per once daily fraction 
followed by two cycles of consolidative chemotherapy after 
the completion of radiation. Patients were randomized 
to receive either 60 or 74 Gy and to receive this with 
or without cetuximab. At the first interim analysis, the 
monitoring committee established that the trial had crossed 
the futility boundary with respect to the 74 Gy arm, and 
this high dose arm was closed. The trial continued accruing 
only at the 60 Gy arm. At the third interim analysis, it was 
established that the cetuximab arm had also crossed the 
futility boundary. 
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The published results of 0617 showed significant 
increased rates of death in the 74 Gy arm, challenging the 
assumption established in the earlier phase I/II studies that 
radiotherapy dose escalation with conventional fractionation 
and concurrent chemotherapy will improve outcomes (14). 
The median survival was 28.7 months in the 60 Gy arm 
versus 19.5 months in the 74 Gy arm (P=0.0007; HR 1.56, 
95% CI: 1.19–2.06) (5). There was a 37% increased risk of 
local failure in the high dose arms (P=0.0319, HR 1.37, 95% 
CI: 0.99–1.89). There was no difference in severe (Common 
Terminology Criteria for Adverse Events grade ≥3) toxic 
effects overall, in severe pulmonary events specifically, or in 
severe radiation pneumonitis between the radiation therapy 
dose groups. Severe esophagitis was more common in the 
high-dose group (21% vs. 16%, P<0.0001). On multivariate 
analyses, factors predicting worse overall survival were 
maximum esophagitis grade, planning target volume size, 
heart dose, and radiation dose. 
The poor survival with treatment to 74 Gy has been 
attributed to several causes. Treatment-related deaths were 
more common in the high-dose group than in the low-
dose group (10 vs. 2), but this comparison did not reach 
statistical significance. Concurrent chemotherapy was 
more difficult to complete in the high-dose group than 
in the low-dose group. Rates of protocol non-compliance 
were greater in the high-dose arm, 26% vs. 17% (P=0.02), 
as were treatment delays. Radiation therapy planning was 
more likely to be non-compliant in the high-dose group, 
and planning target volume coverage by the 95% isodose 
line was poorer in the high-dose group. Concerns that non-
compliance in the high-dose groups produced these results 
led to analysis of overall survival only in those patients with 
radiation plans compliant with the protocol; nevertheless, 
overall survival was still better in the standard-dose groups 
than in the high-dose groups.
The fact that heart dose was a significant predictor 
of overall survival on the multivariate analysis of RTOG 
0617 strongly suggests that it is not only dose to tumor 
that should be considered in future studies. While further 
analysis of RTOG 0617 is pending, three retrospective 
studies also suggest heart dose can predict overall survival 
and cardiac events. The largest with 322 patients identified 
higher doses as important for overall survival and generated 
a new and more conservative heart constraint of V50 <25%, 
or letting no more than 25% of the heart exceed 50 Gy (15). 
Two smaller series of 125 and 112 patients focused on 
cardiac events and showed mean heart dose was important 
(16,17). A secondary analysis of RTOG 0617 showed that 
patients treated at centers with high trial accrual, a potential 
surrogate for number of NSCLC patients treated annually, 
had better survival, lower esophageal and heart doses, 
and lower lethal events (18). Radiation associated cardiac 
toxicity after treatment of locally advanced NSCLC may 
occur earlier than historically understood, and thus heart 
doses should be minimized with any future attempts at dose 
escalation. 
Likely due to PET staging and modern radiation 
therapy techniques, the 28.7-month median survival in 
the 60 Gy arm was longer than that seen in previous 
studies, was better than anticipated, and set a new 
benchmark for patients with locally advanced NSCLC 
receiving concurrent chemotherapy and radiation therapy. 
Consequently, current trials in the United States such 
as RTOG 1306 and National Research Group (NRG) 
L001 have adopted 60 Gy as the standard, as well as the 
American Society for Radiation Oncology (ASTRO) in 
its guidelines (19). The National Comprehensive Cancer 
Network (NCCN) guidelines in the United States now 
suggest definitive radiation should be 60 to 70 Gy (20). 
The European Society for Medical Oncology guidelines 
state that “dose in excess of 66 Gy is not recommended 
outside trials” (21). The Cancer Council of Australia (CCA) 
says that radiation dose “should be at least 60 Gy assuming 
that dose-volume constraints on organs at risk are met” 
and that “74 Gy is not better than 60 Gy and may be 
potentially harmful” (22). Many other national guidelines, 
such as China’s from 2015 (23), do not make explicit dose 
recommendations yet.
Hyperfractionation
Not all patients will be felt fit enough to tolerate concurrent 
treatment with chemotherapy, however, and many of 
those same national guidelines recommend accelerated 
hyperfractionation in such patients. The National Institute 
for Health and Care Excellence (NICE) and CCA both 
recommend continuous hyperfractionated accelerated 
radiation therapy (CHART) when only radiation therapy 
will be used as treatment. Acceleration refers to finishing 
treatment more rapidly than is done conventionally. 
Hyperfractionation refers to dividing treatment into 
smaller doses more than once a day. The CHART trial 
compared 36 fractions of 1.5 Gy given three times per 
day to a total dose of 54 Gy in 12 consecutive days with 
30 fractions of 2 Gy once a day to a total dose of 60 Gy in 
6 weeks. CHART improved 2-year overall survival from 
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20% to 29% (P=0.008). The majority of patients (81%) had 
squamous cell cancer, and in such patients, 2-year overall 
survival improved from 20% to 33% (P=0.0007) (24). 
This regimen has never been directly compared to 
conventional chemoradiation in a randomized trial, 
however. An individual patient data meta-analysis showed 
that hyperfractionation improved overall survival by 2.5% 
at 5 years without improving progression free survival when 
compared to conventionally fractionated radiation alone. 
This came at the risk of worse acute esophageal toxicity 
(odds ratio of 2.44 in NSCLC) (25). The theory is that 
prolongation of treatment results in increased tumor cell 
repopulation (26), and has been proposed as one reason why 
the high dose arm of RTOG 0617 failed. 
However, the CHART regimen is inconvenient as many 
centers are closed on weekends, and it often requires that 
the patients be hospitalized. The randomized phase III 
CHARTWEL (continuous hyperfractionated accelerated 
radiotherapy weekend less) looked at 60 Gy in 40 fractions 
over 2.5 weeks versus 66 Gy in 33 fractions over 6.5 weeks. 
In contrast to CHART, CHARTWEL showed no difference 
in overall survival and local tumor control. Exploratory 
analysis suggested trends for improved local control with 
hyperfractionation for higher stages of disease and after 
neoadjuvant chemotherapy. Histology did not affect 
control, and it should be noted that 58% of patients had 
squamous cell cancers, in contrast to the 81% in CHART 
where hyperfractionation showed the most promise in this 
histology. Another potential explanation for the lack of 
difference in overall survival was the fact that total radiation 
doses were 10% higher in both arms of CHARTWEL 
when compared to CHART (27). 
Hyper f rac t ionated  rad ia t ion  wi th  concurrent 
chemotherapy has also been compared to the combination 
with conventional radiation. A 2×2 trial randomizing 60 Gy 
in 30 fractions in either 6 weeks once a day or 3 weeks 
twice a day with or without concurrent carboplatin showed 
no statistically significant difference in local recurrence 
or survival in all arms (28). RTOG 9410 showed that 
concurrent chemotherapy with hyperfractionated radiation 
to 69.6 Gy had statistically similar 5-year overall survival 
when compared to conventional chemoradiation to 63 Gy, 
13% vs. 16% (P=0.46). Grade 3 esophagitis was statistically 
worse at 45% with hyperfractionation, double that of 22% 
with conventional fractionation (P<0.001) (29). When 
coupled with the logistical issues of delivering multiple 
fractions per day and patient inconvenience, for patients 
felt fit enough for concurrent treatment, conventional 
fractionation became standard in future trials.
Hypofractionation
Most recent studies have investigated accelerating 
treatment with hypofractionation with larger radiation 
doses  de l i vered  once  per  day,  r a ther  than  wi th 
hyperfractionation and its smaller doses delivered more 
than once per day. Concerns about serious toxicity delayed 
exploration of hypofractionation until technology such 
as CT based planning, daily image guidance, and gating 
became widespread. Most reports have been for modest 
hypofractionation of 2–3 Gy per fraction. In patients 
receiving radiation alone, three studies comparing standard 
fractionation to hypofractionation did not report any 
significant differences in toxicity or disease outcomes 
(30-32). In a review of 22 studies of hypofractionated 
radiation alone, Kaster et al. found the weighted mean acute 
toxicity in the esophagus and lung being 1.9% and 1.2% 
respectively. Late toxicity was also low at 1.4% and 6.9%. 
Two-year overall survival ranged from 18% to 42%. There 
was a moderate linear relationship between biologically 
effective lesional dose (BED10): for every 1 Gy increase 
in BED10, there was an absolute overall survival benefit 
ranging from 0.36% to 0.70% (33). This is similar to the 
results found by Machtay et al. with conventional radiation 
where a 1 Gy increase in BED resulted in a 4% relative 
improvement in survival (14), with in the context of 15% 
long-term survival, is an absolute improvement of 0.6%.
Hypofractionation may allow for better outcomes by 
increasing BED without lengthening treatment time and 
thereby preventing cancer cell repopulation. Studies of 
modest hypofractionation with concurrent chemotherapy 
are fewer and mostly single arm, single institution studies. 
In the same systemic review by Kaster et al., 15 studies 
of hypofractionated radiation therapy with concurrent 
chemotherapy were found. The weighted mean acute 
toxicity in the esophagus and lung was 14.9% and 7.9% 
respectively, and for weighted mean late toxicity in the 
esophagus and lung, 6.6% and 12.2%. In comparison, 
RTOG 0617 showed acute grade 3 esophagitis in 7% 
and grade 3 pneumonitis in 4% with late toxicity rates 
<1% for both. Two-year overall survival with concurrent 
hypofractionation ranged from 24% to 58%. The 2-year 
overall survival in RTOG 0617’s standard arm was 58% (5). 
In the United Kingdom, 55 Gy in 20 fractions of 2.75 Gy is 
the most commonly used schedule, both with and without 
concurrent systemic therapy (34).
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More aggressive hypofractionation to 4 Gy per fraction 
has been also been explored in patients not felt fit for 
concurrent chemotherapy. MD Anderson used protons 
to escalate to 60 Gy cobalt-equivalent in 15 fractions 
in a phase 1 trial. At a median follow-up of 13 months, 
two of 25 patients experienced dose-limiting toxicities. 
One treated to 52.5 Gy cobalt-equivalent in 15 fractions 
developed a tracheoesophageal fistula after bevacizumab 
was delivered for recurrent disease. The second developed 
“possible” grade 3 radiation pneumonitis (35). This regimen 
with protons is currently being explored with concurrent 
chemotherapy in a phase I study at our institution 
(NCT02172846).
As protons are not available at most centers, a phase 1 
dose escalation study was later reported using photons at 
University of Texas Southwestern in patients who were 
not chemotherapy candidates. It enrolled 55 patients 
divided between 50, 55, and 60 Gy, all in 15 fractions. 
One patient developed grade 3 esophagitis, and 2 cases of 
grade 3 dyspnea were felt related to therapy. There was 
no association between fraction size and toxicity (P=0.24), 
and the median overall survival was 6 months at all dose 
levels (P=0.59) (36). This same group has presented in 
abstract form an interim analysis from a randomized 
phase III comparison of 60 Gy in 15 vs. 30 fractions of 
image-guided photon radiation therapy in patients with a 
Zubrod performance status of 2 or greater. Median overall 
survival for the 48 patients evaluable was 11.5 months 
with no statistical difference between conventional and 
hypofractionated radiation treatment arms. Two deaths 
from hypoxia with conventional radiation and 1 death 
with hypofractionated radiation were possibly related to 
treatment (37). Final results are pending, but the study 
authors feel the results could potentially change the 
paradigm of treatment for patients with locally advanced 
disease receiving radiation alone due to poor performance 
status.
Adapted therapy
Rather than prescribing the same fixed dose to all 
patients with locally advanced disease, isotoxic radiation 
therapy is a novel approach which allows for personalized 
treatment planning based on individual tumor and patient 
characteristics. This tailored approach is heavily based 
upon predefined organ at risk dose constraints. Treatment 
plans are designed to give the maximum BED achievable 
to the tumor target until the predefined dose constraints 
are reached. The increasing use of computer-based inverse-
planned intensity modulated radiation therapy (IMRT) 
makes this approach especially feasible.
One  such  approach  w i th  hyper f r ac t iona t ion , 
individualized isotoxic accelerated radiotherapy (INDAR) 
has been used for over a decade in the Netherlands. In 
the first three weeks, 30 twice daily fractions of 1.5 Gy are 
delivered. Next, 2 Gy fractions once a day are delivered 
until a mean lung dose of 19 Gy is reached, with a total 
ranging between 54 to 69 Gy in 5.5 weeks. The equivalent 
conventional dose would be 72 Gy over 36 fractions. Long 
term results showed that with sequential chemotherapy 
and INDAR, the median survival was 23.6 months. For 
comparison, the use of sequential chemotherapy and 
conventional fractionation with the same group resulted in a 
lower median survival of only 17.5 months (38). The use of 
concurrent chemotherapy in a phase 1 study with INDAR 
showed no dose limiting toxicity (39).
Instead of hyperfractionation, other institutions have 
used isotoxic planning with hypofractionation. A single 
institution phase I trial used 25 fractions ranging from 2.28 
to 3.42 Gy (a total of 57 to 85.5 Gy) with IMRT. Total dose 
was escalated according to each patient’s individual stratified 
risk for radiation pneumonitis. The maximum tolerated 
dose was predefined as the dose that theoretically would 
result in ≤20% risk of severe toxicity. Grade 4 to 5 toxicity 
was reached late in 6 of the 79 patients, and the maximum 
tolerated dose was defined as 63.25 Gy in 25 fractions of 
2.53 Gy each. These severe toxicities were due to damage 
to the central and perihilar structures and corresponded to 
dose to the proximal bronchial tree (40).
RTOG 1106, which recently completed accrual, coupled 
the use of isotoxic hypofractionation with metabolic imaging 
to adapt chemoradiation treatment for locally advanced 
disease. The control arm was standard fractionation of 
60 Gy in 30 fractions of 2 Gy each. In the experimental 
arm, the first 21 fractions were 2.2 Gy each. The final nine 
fractions were delivered only to residual disease seen on a 
PET taken after fractions 18 or 19. Residual disease was 
defined as any sites with metabolic activity at least 150% 
that of the aortic arch. These final nine fractions could 
range from 2.2–3.8 Gy per fraction, corresponding to a 
range of 19.8 to 34.2 Gy. The highest achievable dose was 
given while still respecting a mean lung dose of 20 Gy. The 
theoretical maximum tumor dose was 80.4 Gy. Patients 
were randomized 2:1 into the experimental arm with 
stratification by stage, primary tumor size, and histology. 
The primary objective was local control, and results are 
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pending.
RTOG 1106 was based on studies from University 
of Michigan which demonstrated that tumors decrease 
more in metabolic activity than size during treatment. 
Recently, this group reported on the results of a phase II 
study of conformal radiation individualized to a fixed risk 
of radiation-induced lung toxicity of 17.2% for grade 2 or 
greater pneumonitis. Dose to residual tumor was adaptively 
escalated to residual tumor on a mid-treatment PET up to a 
total dose of 86 Gy in 30 fractions. The median tumor dose 
delivered was 83 Gy over 30 fractions. The initial doses per 
fraction were 2.1 to 2.85 Gy initially over 18–24 fractions, 
then 2.85 to 5.0 Gy for the adaptive phase after the mid-
treatment PET. Most patients (93%) received concurrent 
carboplatin and paclitaxel with consolidation chemotherapy. 
With a median follow-up for surviving patients of 
47 months, the 2-year rate of infield tumor control was 
82% with a median overall survival of 25 months (41). 
Rather than using mid-treatment imaging, other groups 
have looked at boosting any residual disease after the 
completion of conventional treatment with stereotactic 
body radiation therapy (SBRT). SBRT has proven very 
effective in early stage disease, especially in lesions far 
from major airways and the mediastinum (42). With SBRT, 
BEDs of at least 100 Gy total are typically delivered in 
3–5 fract ions with narrow margins.  Four studies 
have looked at a SBRT boost to residual disease after 
conventional chemoradiation therapy to 50–60 Gy. In 
these small series with limited follow-up, local control at 
one year has been approximately 80% (43-46), comparable 
to that of RTOG 0617, which was a mixed group that 
contained patients who had a complete response. Of the 
80 patients in these four studies of SBRT boosts, there 
have been 5 (6.3%) lethal toxicities such as pulmonary 
hemorrhage, particularly with boosts to central disease 
near the main airways and mediastinum. 
A multi-institutional trial has been proposed that would 
use a SBRT boost to metabolically active residual disease 
seen on PET-CT 2–4 weeks after chemoradiation treatment 
completion (47). Patients with a complete response would 
be observed. The benchmark for trial success would be 
that in patients with residual disease after conventional 
treatment, a SBRT boost would result in progression-
free survival of 20–30% at 2 years, matching that seen in 
RTOG 0617. Now with immunotherapy recently showing 
a progression free benefit when used after conventional 
chemoradiation (48), SBRT becomes even more attractive 
as a boost as it could theoretically better present tumor 
antigens and better serve as a potentiator of the patient’s 
own immune system against their disease (49).
Conclusions
Locally advanced NSCLC remains a challenging disease 
with significant mortality and complications. Efforts to 
improve treatment outcomes have been only moderately 
successful, but the combination of hypofractionation with 
systemic therapy, individualized treatment adaptation, and 
stereotactic boosts in the era of immunotherapy offers the 
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